Tokyo Tape
Sign in
← H.U. Group Holdings

Half-year report · HY

4544.TEDINET S100X1GC
Period2025-04-01 → 2025-09-30
Filed2025-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 45
MetricValuePeriodScopeSource row
Revenue¥124.4bn2025-04-01 → 2025-09-30Cons.Net sales
Revenue¥243.0bn2024-04-01 → 2025-03-31Cons.Net sales (5-year summary)
Revenue¥120.0bn2024-04-01 → 2024-09-30Cons.Net sales
Operating income¥2.3bn2025-04-01 → 2025-09-30Cons.Operating income
Operating income¥956m2024-04-01 → 2024-09-30Cons.Operating income
Ordinary income¥305m2025-04-01 → 2025-09-30Cons.Ordinary income
Ordinary income¥4.7bn2024-04-01 → 2025-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income−¥1.3bn2024-04-01 → 2024-09-30Cons.Ordinary income
Profit before tax−¥187m2025-04-01 → 2025-09-30Cons.Income before income taxes
Profit before tax−¥1.6bn2024-04-01 → 2024-09-30Cons.Income before income taxes
Net income (owners)¥205m2025-04-01 → 2025-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥2.8bn2024-04-01 → 2025-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥821m2024-04-01 → 2024-09-30Cons.Profit loss attributable to owners of parent
Net income¥142m2025-04-01 → 2025-09-30Cons.Profit loss
Net income−¥821m2024-04-01 → 2024-09-30Cons.Profit loss
Total assets¥274.0bnat 2025-09-30Cons.Assets
Total assets¥279.6bnat 2025-03-31Cons.Assets
Total assets¥291.4bnat 2024-09-30Cons.Total assets (5-year summary)
Total liabilities¥138.9bnat 2025-09-30Cons.Liabilities
Total liabilities¥142.3bnat 2025-03-31Cons.Liabilities
Net assets / equity¥135.1bnat 2025-09-30Cons.Net assets
Net assets / equity¥137.3bnat 2025-03-31Cons.Net assets
Net assets / equity¥136.1bnat 2024-09-30Cons.Net assets (5-year summary)
Cash and deposits¥39.6bnat 2025-09-30Cons.Cash and deposits
Cash and deposits¥40.9bnat 2025-03-31Cons.Cash and deposits
Cash & equivalents¥39.6bnat 2025-09-30Cons.Cash and cash equivalents
Cash & equivalents¥40.9bnat 2025-03-31Cons.Cash and cash equivalents
Cash & equivalents¥47.0bnat 2024-09-30Cons.Cash and cash equivalents
Cash & equivalents¥39.9bnat 2024-03-31vCons.Cash and cash equivalents
Operating cash flow¥6.2bn2025-04-01 → 2025-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥22.0bn2024-04-01 → 2025-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥6.7bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥2.0bn2025-04-01 → 2025-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥16.0bn2024-04-01 → 2025-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥9.8bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥5.8bn2025-04-01 → 2025-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥5.3bn2024-04-01 → 2025-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow¥10.7bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥3.612025-04-01 → 2025-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥48.62024-04-01 → 2025-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-14.472024-04-01 → 2024-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥3.612025-04-01 → 2025-09-30Cons.Diluted earnings per share (5-year summary)
Equity ratio49.2%at 2025-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio49.0%at 2025-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio46.7%at 2024-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 38
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2025-04-01 → 2025-09-30−¥2.3bn
Reconciling Itemsreconcilingrevenue intersegment2025-04-01 → 2025-09-30−¥2.3bn
Reconciling Itemsreconcilingsegment profit2025-04-01 → 2025-09-30−¥2.7bn
Clinical Lab Testing Businessreportable segmentrevenue2025-04-01 → 2025-09-30¥79.4bn
Clinical Lab Testing Businessreportable segmentrevenue external2025-04-01 → 2025-09-30¥79.2bn
Clinical Lab Testing Businessreportable segmentrevenue intersegment2025-04-01 → 2025-09-30¥249m
Clinical Lab Testing Businessreportable segmentsegment profit2025-04-01 → 2025-09-30−¥930m
In Vitro Diagnostics Businessreportable segmentrevenue2025-04-01 → 2025-09-30¥31.4bn
In Vitro Diagnostics Businessreportable segmentrevenue external2025-04-01 → 2025-09-30¥29.4bn
In Vitro Diagnostics Businessreportable segmentrevenue intersegment2025-04-01 → 2025-09-30¥2.0bn
In Vitro Diagnostics Businessreportable segmentsegment profit2025-04-01 → 2025-09-30¥4.8bn
Sterilization And Related Servicesreportable segmentrevenue2025-04-01 → 2025-09-30¥15.9bn
Sterilization And Related Servicesreportable segmentrevenue external2025-04-01 → 2025-09-30¥15.8bn
Sterilization And Related Servicesreportable segmentrevenue intersegment2025-04-01 → 2025-09-30¥90m
Sterilization And Related Servicesreportable segmentsegment profit2025-04-01 → 2025-09-30¥1.2bn
—segment totalrevenue2025-04-01 → 2025-09-30¥126.7bn
—segment totalrevenue external2025-04-01 → 2025-09-30¥124.4bn
—segment totalrevenue intersegment2025-04-01 → 2025-09-30¥2.3bn
—segment totalsegment profit2025-04-01 → 2025-09-30¥5.1bn
Reconciling Itemsreconcilingrevenue2024-04-01 → 2024-09-30−¥2.4bn
Reconciling Itemsreconcilingrevenue intersegment2024-04-01 → 2024-09-30−¥2.4bn
Reconciling Itemsreconcilingsegment profit2024-04-01 → 2024-09-30−¥2.5bn
Clinical Lab Testing Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥76.7bn
Clinical Lab Testing Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥76.5bn
Clinical Lab Testing Businessreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥205m
Clinical Lab Testing Businessreportable segmentsegment profit2024-04-01 → 2024-09-30−¥2.9bn
In Vitro Diagnostics Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥31.2bn
In Vitro Diagnostics Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥29.0bn
In Vitro Diagnostics Businessreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥2.2bn
In Vitro Diagnostics Businessreportable segmentsegment profit2024-04-01 → 2024-09-30¥5.5bn
Sterilization And Related Servicesreportable segmentrevenue2024-04-01 → 2024-09-30¥14.5bn
Sterilization And Related Servicesreportable segmentrevenue external2024-04-01 → 2024-09-30¥14.4bn
Sterilization And Related Servicesreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥9m
Sterilization And Related Servicesreportable segmentsegment profit2024-04-01 → 2024-09-30¥879m
—segment totalrevenue2024-04-01 → 2024-09-30¥122.4bn
—segment totalrevenue external2024-04-01 → 2024-09-30¥120.0bn
—segment totalrevenue intersegment2024-04-01 → 2024-09-30¥2.4bn
—segment totalsegment profit2024-04-01 → 2024-09-30¥3.5bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 524
ItemContextValueUnit
Net assetsPrior1YearInstant137295000000JPY
Net assetsInterimInstant135129000000JPY
Liabilities and net assetsPrior1YearInstant279582000000JPY
Liabilities and net assetsInterimInstant274018000000JPY
Net salesPrior1InterimDuration119987000000JPY
Net salesInterimDuration124392000000JPY
Cost of salesPrior1InterimDuration87299000000JPY
Cost of salesInterimDuration88016000000JPY
Gross profitPrior1InterimDuration32687000000JPY
Gross profitInterimDuration36376000000JPY
Selling general and administrative expensesPrior1InterimDuration31731000000JPY
Selling general and administrative expensesInterimDuration34049000000JPY
Operating incomePrior1InterimDuration956000000JPY
Operating incomeInterimDuration2326000000JPY
Interest income noiPrior1InterimDuration249000000JPY
Interest income noiInterimDuration225000000JPY
Dividends income noiPrior1InterimDuration40000000JPY
Dividends income noiInterimDuration35000000JPY
Other noiPrior1InterimDuration178000000JPY
Other noiInterimDuration227000000JPY
Non operating incomePrior1InterimDuration468000000JPY
Non operating incomeInterimDuration488000000JPY
Interest expenses noePrior1InterimDuration238000000JPY
Interest expenses noeInterimDuration343000000JPY
Equity in losses of affiliates noePrior1InterimDuration617000000JPY
Equity in losses of affiliates noeInterimDuration1082000000JPY
Other noePrior1InterimDuration1826000000JPY
Other noeInterimDuration1083000000JPY
Non operating expensesPrior1InterimDuration2682000000JPY
Non operating expensesInterimDuration2508000000JPY
Ordinary incomePrior1InterimDuration-1257000000JPY
Ordinary incomeInterimDuration305000000JPY
Gain on sales of investment securities eiPrior1InterimDuration－JPY
Gain on sales of investment securities eiInterimDuration78000000JPY
Reversal of provision for compensation loss elPrior1InterimDuration678000000JPY
Reversal of provision for compensation loss elInterimDuration－JPY
Other eiPrior1InterimDuration3000000JPY
Other eiInterimDuration23000000JPY
Extraordinary incomePrior1InterimDuration681000000JPY
Extraordinary incomeInterimDuration102000000JPY
Loss on retirement of noncurrent assets elPrior1InterimDuration125000000JPY
Loss on retirement of noncurrent assets elInterimDuration299000000JPY
Loss on liquidation of subsidiaries and affiliates general elPrior1InterimDuration817000000JPY
Loss on liquidation of subsidiaries and affiliates general elInterimDuration－JPY
Provision for compensation loss elPrior1InterimDuration－JPY
Provision for compensation loss elInterimDuration226000000JPY
Other elPrior1InterimDuration52000000JPY
Other elInterimDuration69000000JPY
Extraordinary lossPrior1InterimDuration995000000JPY
Extraordinary lossInterimDuration595000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2025-03-31pass
balance sheet identityconsolidated 2025-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2025-03-31pass
statement vs summary · net assetsconsolidated 2025-09-30pass
statement vs summary · net income attributable to parentconsolidated 2024-04-01/2024-09-30pass
statement vs summary · net income attributable to parentconsolidated 2025-04-01/2025-09-30pass
statement vs summary · operating cash flowconsolidated 2024-04-01/2024-09-30pass
statement vs summary · operating cash flowconsolidated 2025-04-01/2025-09-30pass
statement vs summary · revenueconsolidated 2024-04-01/2024-09-30pass
statement vs summary · revenueconsolidated 2025-04-01/2025-09-30pass
statement vs summary · total assetsconsolidated 2025-03-31pass
statement vs summary · total assetsconsolidated 2025-09-30pass